Finanzen von Immunome Inc (IMNM)IMNMImmunome Inc

Evaluating the bottom line, Immunome, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -64.03%, provide a clear picture of how effectively IMNM converts its operational activities into shareholder value.

In the context of the broader market, IMNM competes directly with industry leaders such as PHVS and ALVO. With a market capitalization of $2.28B, it holds a leading position in the sector. When comparing efficiency, IMNM's gross margin of N/A stands against PHVS's N/A and ALVO's 50.71%. Such benchmarking helps identify whether Immunome, Inc. is trading at a premium or discount relative to its financial performance.

Immunome's gross margin has been consistently at 100% until Q1 2026, but it dropped to 0% in Q2 2026. The company reported a net income of -$73.1 million in Q2 2026, highlighting significant losses.